{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:16:27Z","timestamp":1794107787929,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11030-023-10805-5","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T04:25:54Z","timestamp":1708143954000},"page":"4151-4165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Taming the cytokine storm: small molecule inhibitors targeting IL-6\/IL-6\u03b1 receptor"],"prefix":"10.1007","volume":"28","author":[{"given":"Komal","family":"Zia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Nur-e-Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aftab","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaheer","family":"Ul-Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,17]]},"reference":[{"key":"10805_CR1","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH (2020) Cytokine storm. N Engl J Med 383:2255\u20132273. https:\/\/doi.org\/10.1056\/NEJMra2026131","journal-title":"N Engl J Med"},{"key":"10805_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"10805_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clindermatol.2020.12.015","volume":"39","author":"N Fagan","year":"2021","unstructured":"Fagan N, Meah N, York K et al (2021) Shedding light on therapeutics in alopecia and their relevance to COVID-19. Clin Dermatol 39:76\u201383. https:\/\/doi.org\/10.1016\/j.clindermatol.2020.12.015","journal-title":"Clin Dermatol"},{"key":"10805_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","volume":"40","author":"S Hojyo","year":"2020","unstructured":"Hojyo S, Uchida M, Tanaka K et al (2020) How COVID-19 induces cytokine storm with high mortality. Inflamm Regener 40:37. https:\/\/doi.org\/10.1186\/s41232-020-00146-3","journal-title":"Inflamm Regener"},{"key":"10805_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102833","volume":"57","author":"C Wang","year":"2020","unstructured":"Wang C, Xie J, Zhao L et al (2020) Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients. eBioMedicine 57:e102833. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102833","journal-title":"eBioMedicine"},{"key":"10805_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"10805_CR7","doi-asserted-by":"publisher","first-page":"E005","DOI":"10.3760\/cma.j.issn.1001-0939.2020.0005","volume":"43","author":"L Chen","year":"2020","unstructured":"Chen L, Liu HG, Liu W et al (2020) Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 43:E005. https:\/\/doi.org\/10.3760\/cma.j.issn.1001-0939.2020.0005","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10805_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.medmal.2020.04.002","volume":"50","author":"ZS Ulhaq","year":"2020","unstructured":"Ulhaq ZS, Soraya GV (2020) Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect 50:382\u2013383. https:\/\/doi.org\/10.1016\/j.medmal.2020.04.002","journal-title":"Med Mal Infect"},{"key":"10805_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1165\/rcmb.2020-0277LE","volume":"63","author":"TL Hedrick","year":"2020","unstructured":"Hedrick TL, Murray BP, Hagan RS, Mock JR (2020) COVID-19: clean up on IL-6. Am J Respir Cell Mol Biol 63:541\u2013543. https:\/\/doi.org\/10.1165\/rcmb.2020-0277LE","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10805_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2141","volume":"30","author":"EA Coomes","year":"2020","unstructured":"Coomes EA, Haghbayan H (2020) Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol 30:e2141. https:\/\/doi.org\/10.1002\/rmv.2141","journal-title":"Rev Med Virol"},{"key":"10805_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s12325-022-02042-3","volume":"39","author":"L Villaescusa","year":"2022","unstructured":"Villaescusa L, Zaragoz\u00e1 F, Gayo-Abeleira I, Zaragoz\u00e1 C (2022) A new approach to the management of COVID-19. Antagonists of IL-6: siltuximab. Adv Ther 39:1126\u20131148. https:\/\/doi.org\/10.1007\/s12325-022-02042-3","journal-title":"Adv Ther"},{"key":"10805_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102452","volume":"111","author":"B Liu","year":"2020","unstructured":"Liu B, Li M, Zhou Z et al (2020) Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 111:102452. https:\/\/doi.org\/10.1016\/j.jaut.2020.102452","journal-title":"J Autoimmun"},{"key":"10805_CR13","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.7150\/ijbs.4989","volume":"8","author":"S Rose-John","year":"2012","unstructured":"Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8:1237\u20131247. https:\/\/doi.org\/10.7150\/ijbs.4989","journal-title":"Int J Biol Sci"},{"key":"10805_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1517\/14728222.11.5.613","volume":"11","author":"S Rose-John","year":"2007","unstructured":"Rose-John S, Waetzig GH, Scheller J et al (2007) The IL-6\/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11:613\u2013624. https:\/\/doi.org\/10.1517\/14728222.11.5.613","journal-title":"Expert Opin Ther Targets"},{"key":"10805_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234\u2013248. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8","journal-title":"Nat Rev Clin Oncol"},{"key":"10805_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/1535-7163.MCT-11-0850","volume":"11","author":"O Yamada","year":"2012","unstructured":"Yamada O, Ozaki K, Akiyama M, Kawauchi K (2012) JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells. Mol Cancer Ther 11:1112\u20131121. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0850","journal-title":"Mol Cancer Ther"},{"key":"10805_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","volume":"519","author":"K Taniguchi","year":"2015","unstructured":"Taniguchi K, Wu L-W, Grivennikov SI et al (2015) A gp130\u2013Src\u2013YAP module links inflammation to epithelial regeneration. Nature 519:57\u201362. https:\/\/doi.org\/10.1038\/nature14228","journal-title":"Nature"},{"key":"10805_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ (2017) Mechanisms and consequences of Jak\u2013STAT signaling in the immune system. Nat Immunol 18:374\u2013384. https:\/\/doi.org\/10.1038\/ni.3691","journal-title":"Nat Immunol"},{"key":"10805_CR19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2016) Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8:959\u2013970. https:\/\/doi.org\/10.2217\/imt-2016-0020","journal-title":"Immunotherapy"},{"key":"10805_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W et al (2018) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23:943\u2013947. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028","journal-title":"Oncologist"},{"key":"10805_CR21","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/1078-0432.CCR-14-1678","volume":"21","author":"A Deisseroth","year":"2015","unstructured":"Deisseroth A, Ko C-W, Nie L et al (2015) FDA approval: siltuximab for the treatment of patients with multicentric castleman disease. Clin Cancer Res 21:950\u2013954. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1678","journal-title":"Clin Cancer Res"},{"key":"10805_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40290-020-00342-z","volume":"34","author":"S Atal","year":"2020","unstructured":"Atal S, Fatima Z (2020) IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharm Med 34:223\u2013231. https:\/\/doi.org\/10.1007\/s40290-020-00342-z","journal-title":"Pharm Med"},{"key":"10805_CR23","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo Y, Xu F, Lu T et al (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38:904\u2013910. https:\/\/doi.org\/10.1016\/j.ctrv.2012.04.007","journal-title":"Cancer Treat Rev"},{"key":"10805_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115327","volume":"28","author":"S Kaur","year":"2020","unstructured":"Kaur S, Bansal Y, Kumar R, Bansal G (2020) A panoramic review of IL-6: structure, pathophysiological roles and inhibitors. Bioorg Med Chem 28:115327. https:\/\/doi.org\/10.1016\/j.bmc.2020.115327","journal-title":"Bioorg Med Chem"},{"key":"10805_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers C, Heink S, Korn T, Rose-John S (2018) Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17:395\u2013412. https:\/\/doi.org\/10.1038\/nrd.2018.45","journal-title":"Nat Rev Drug Discov"},{"key":"10805_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John S, Jenkins BJ, Garbers C et al (2023) Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol 23:666\u2013681. https:\/\/doi.org\/10.1038\/s41577-023-00856-y","journal-title":"Nat Rev Immunol"},{"key":"10805_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448\u2013457. https:\/\/doi.org\/10.1038\/ni.3153","journal-title":"Nat Immunol"},{"key":"10805_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ (2018) Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 18:773\u2013789. https:\/\/doi.org\/10.1038\/s41577-018-0066-7","journal-title":"Nat Rev Immunol"},{"key":"10805_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, Dunwiddie CT et al (2010) How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discov 9:203\u2013214. https:\/\/doi.org\/10.1038\/nrd3078","journal-title":"Nat Rev Drug Discov"},{"key":"10805_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2174\/1570180819666220405225817","volume":"19","author":"IJTM de NascimentoAquino","year":"2022","unstructured":"de NascimentoAquino IJTM, da Silva-J\u00fanior EF (2022) The new era of drug discovery: the power of Computer-aided Drug Design (CADD). Lett Drug Des Discov 19:951\u2013955. https:\/\/doi.org\/10.2174\/1570180819666220405225817","journal-title":"Lett Drug Des Discov"},{"key":"10805_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202200693","volume":"18","author":"V Pratap Reddy Gajulapalli","year":"2023","unstructured":"Pratap Reddy Gajulapalli V (2023) Development of kinase-centric drugs: a computational perspective. ChemMedChem 18:e202200693. https:\/\/doi.org\/10.1002\/cmdc.202200693","journal-title":"ChemMedChem"},{"key":"10805_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198022","volume":"285","author":"AT Onawole","year":"2020","unstructured":"Onawole AT, Sulaiman KO, Kolapo TU et al (2020) COVID-19: CADD to the rescue. Virus Res 285:198022. https:\/\/doi.org\/10.1016\/j.virusres.2020.198022","journal-title":"Virus Res"},{"key":"10805_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8853056","volume":"2021","author":"AB Gurung","year":"2021","unstructured":"Gurung AB, Ali MA, Lee J et al (2021) An updated review of computer-aided drug design and its application to COVID-19. Biomed Res Int 2021:e8853056. https:\/\/doi.org\/10.1155\/2021\/8853056","journal-title":"Biomed Res Int"},{"key":"10805_CR34","doi-asserted-by":"publisher","first-page":"9121","DOI":"10.1039\/D0CS01065K","volume":"50","author":"N","year":"2021","unstructured":"N, Muratov, RH, Amaro, CH, Andrade et al (2021) A critical overview of computational approaches employed for COVID-19 drug discovery. Chem Soc Rev 50:9121\u20139151. https:\/\/doi.org\/10.1039\/D0CS01065K","journal-title":"Chem Soc Rev"},{"key":"10805_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1766572","author":"VK Bhardwaj","year":"2020","unstructured":"Bhardwaj VK, Singh R, Sharma J et al (2020) Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1766572","journal-title":"J Biomol Struct Dyn"},{"key":"10805_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2020.128933","volume":"346","author":"J Sharma","year":"2021","unstructured":"Sharma J, Kumar Bhardwaj V, Singh R et al (2021) An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2. Food Chem 346:128933. https:\/\/doi.org\/10.1016\/j.foodchem.2020.128933","journal-title":"Food Chem"},{"key":"10805_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7772","author":"R Singh","year":"2023","unstructured":"Singh R, Purohit R (2023) Multi-target approach against SARS-CoV-2 by stone apple molecules: a master key to drug design. Phytother Res. https:\/\/doi.org\/10.1002\/ptr.7772","journal-title":"Phytother Res"},{"key":"10805_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104631","volume":"136","author":"R Singh","year":"2021","unstructured":"Singh R, Bhardwaj VK, Sharma J et al (2021) Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors. Comput Biol Med 136:104631. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104631","journal-title":"Comput Biol Med"},{"key":"10805_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104965","volume":"139","author":"R Singh","year":"2021","unstructured":"Singh R, Bhardwaj VK, Purohit R (2021) Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: an in-silico approach. Comput Biol Med 139:104965. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104965","journal-title":"Comput Biol Med"},{"key":"10805_CR40","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/cbf.3753","volume":"40","author":"R Singh","year":"2022","unstructured":"Singh R, Bhardwaj VK, Purohit R (2022) Inhibition of nonstructural protein 15 of SARS-CoV-2 by golden spice: a computational insight. Cell Biochem Funct 40:926\u2013934. https:\/\/doi.org\/10.1002\/cbf.3753","journal-title":"Cell Biochem Funct"},{"key":"10805_CR41","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1126\/science.1083901","volume":"300","author":"MJ Boulanger","year":"2003","unstructured":"Boulanger MJ, Chow D, Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6\/IL-6 \u03b1-receptor\/gp130 complex. Science 300:2101\u20132104. https:\/\/doi.org\/10.1126\/science.1083901","journal-title":"Science"},{"key":"10805_CR42","unstructured":"Molecular Operating Environment (MOE) (2023) 2022.02 Chemical Computing Group ULC, Montreal"},{"key":"10805_CR43","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger MM, Carchia M, JohnJ I, Shoichet BK (2012) Directory of Useful Decoys, Enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 55:6582\u20136594. https:\/\/doi.org\/10.1021\/jm300687e","journal-title":"J Med Chem"},{"key":"10805_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2020.131865","volume":"79","author":"T Lewis-Atwell","year":"2021","unstructured":"Lewis-Atwell T, Townsend PA, Grayson MN (2021) Comparisons of different force fields in conformational analysis and searching of organic molecules: a review. Tetrahedron 79:131865. https:\/\/doi.org\/10.1016\/j.tet.2020.131865","journal-title":"Tetrahedron"},{"key":"10805_CR45","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D, Lindahl E, Hess B et al (2005) GROMACS: fast, flexible, and free. J Comput Chem 26:1701\u20131718. https:\/\/doi.org\/10.1002\/jcc.20291","journal-title":"J Comput Chem"},{"key":"10805_CR46","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1021\/ct200196m","volume":"7","author":"AK Malde","year":"2011","unstructured":"Malde AK, Zuo L, Breeze M et al (2011) An Automated force field topology builder (ATB) and repository: version 1.0. J Chem Theory Comput 7:4026\u20134037. https:\/\/doi.org\/10.1021\/ct200196m","journal-title":"J Chem Theory Comput"},{"key":"10805_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.129953","volume":"1231","author":"K Zia","year":"2021","unstructured":"Zia K, Khan SA, Ashraf S et al (2021) Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease. J Mol Struct 1231:129953. https:\/\/doi.org\/10.1016\/j.molstruc.2021.129953","journal-title":"J Mol Struct"},{"key":"10805_CR48","doi-asserted-by":"publisher","first-page":"10315","DOI":"10.3390\/ijms231810315","volume":"23","author":"SA Khan","year":"2022","unstructured":"Khan SA, Khan A, Zia K et al (2022) Cheminformatics-based discovery of potential chemical probe inhibitors of omicron spike protein. Int J Mol Sci 23:10315. https:\/\/doi.org\/10.3390\/ijms231810315","journal-title":"Int J Mol Sci"},{"key":"10805_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33\u201338. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5","journal-title":"J Mol Graph"},{"key":"10805_CR50","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1080\/07391102.2020.1751298","volume":"39","author":"SA Khan","year":"2021","unstructured":"Khan SA, Zia K, Ashraf S et al (2021) Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J Biomol Struct Dyn 39:2607\u20132616. https:\/\/doi.org\/10.1080\/07391102.2020.1751298","journal-title":"J Biomol Struct Dyn"},{"key":"10805_CR51","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","volume":"54","author":"R Kumari","year":"2014","unstructured":"Kumari R, Kumar R, Lynn A (2014) g_mmpbsa\u2014a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54:1951\u20131962. https:\/\/doi.org\/10.1021\/ci500020m","journal-title":"J Chem Inf Model"},{"key":"10805_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/jcc.21643","volume":"32","author":"D Plewczynski","year":"2011","unstructured":"Plewczynski D, \u0141a\u017aniewski M, Augustyniak R, Ginalski K (2011) Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database. J Comput Chem 32:742\u2013755. https:\/\/doi.org\/10.1002\/jcc.21643","journal-title":"J Comput Chem"},{"key":"10805_CR53","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.drudis.2006.03.009","volume":"11","author":"M Feher","year":"2006","unstructured":"Feher M (2006) Consensus scoring for protein\u2013ligand interactions. Drug Discov Today 11:421\u2013428. https:\/\/doi.org\/10.1016\/j.drudis.2006.03.009","journal-title":"Drug Discov Today"},{"key":"10805_CR54","doi-asserted-by":"publisher","first-page":"12899","DOI":"10.1039\/C0CP00151A","volume":"12","author":"S-Y Huang","year":"2010","unstructured":"Huang S-Y, Grinter SZ, Zou X (2010) Scoring functions and their evaluation methods for protein\u2013ligand docking: recent advances and future directions. Phys Chem Chem Phys 12:12899\u201312908. https:\/\/doi.org\/10.1039\/C0CP00151A","journal-title":"Phys Chem Chem Phys"},{"key":"10805_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/prot.26002","volume":"89","author":"M Gupta","year":"2021","unstructured":"Gupta M, Ha K, Agarwal R et al (2021) Molecular dynamics analysis of the binding of human interleukin-6 with interleukin-6 \u03b1-receptor. Proteins 89:163\u2013173. https:\/\/doi.org\/10.1002\/prot.26002","journal-title":"Proteins"},{"key":"10805_CR56","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1432-1033.1993.tb17605.x","volume":"211","author":"V Fontaine","year":"1993","unstructured":"Fontaine V, Savino R, Arcone R et al (1993) Involvement of the Arg179 in the active site of human IL-6. Eur J Biochem 211:749\u2013755. https:\/\/doi.org\/10.1111\/j.1432-1033.1993.tb17605.x","journal-title":"Eur J Biochem"},{"key":"10805_CR57","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/blood.V89.4.1319","volume":"89","author":"M Kalai","year":"1997","unstructured":"Kalai M, Montero-Julian FA, Gr\u00f6tzinger J et al (1997) Analysis of the human interleukin-6\/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction. Blood 89:1319\u20131333. https:\/\/doi.org\/10.1182\/blood.V89.4.1319","journal-title":"Blood"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-023-10805-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-023-10805-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-023-10805-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:06:37Z","timestamp":1734627997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-023-10805-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,17]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10805"],"URL":"https:\/\/doi.org\/10.1007\/s11030-023-10805-5","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,17]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report there are no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}